SCHEMBL29646646

SCHEMBL29646646

Nc1cc(N)cc(-c2ccc(F)cc2F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
TTR P02766 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
DHFR P00374 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
LMNA P02545 1/20 0.42
ALB P02768 1/20 0.42
HMGB1 P09429 1/20 0.42
HPGD P15428 1/20 0.42
CXCL12 P48061 1/20 0.42
KMT2A Q03164 1/20 0.42
HIF1A Q16665 1/20 0.42
SLC22A6 Q4U2R8 1/20 0.42
ACMSD Q8TDX5 1/20 0.42
HSD17B10 Q99714 1/20 0.42
FEN1 P39748 2/20 0.41
ALOX5AP P20292 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21819775 1.00 ALDH1A1 (0.48) ALDH1A1TTRKDM4EMEN1USP2
SCHEMBL16342565 0.87 PTGS2 (0.45) ALDH1A1TTRKDM4EMEN1USP2
SCHEMBL19433368 0.87 APP (0.43) ALDH1A1TTRKDM4EMEN1USP2
SCHEMBL16395977 0.87 ALDH1A1 (0.41) ALDH1A1TTRKDM4EMEN1USP2
SCHEMBL11545227 0.83 TAAR1 (0.50) ALDH1A1TTRKDM4EMEN1USP2
SCHEMBL16396000 0.82 GABRG2 (0.45) ALDH1A1TTRKDM4EMEN1USP2
SCHEMBL16402118 0.82 TTR (0.38) ALDH1A1TTRKDM4EMEN1USP2
SCHEMBL957126 0.82 PDE3B (0.47) ALDH1A1TTRKDM4EMEN1USP2
SCHEMBL16396242 0.80 FEN1 (0.44) FEN1ALOX5APCLK1
SCHEMBL14926554 0.79 TTR (0.46) ALDH1A1TTRKDM4EMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115124470-B Method for preparing sulfonamide structured kinase inhibitors 奥瑞基尼肿瘤有限公司 2024-08-27 CN claimed
CN-115124470-B Method for preparing sulfonamide structured kinase inhibitors 奥瑞基尼肿瘤有限公司 2024-08-27 CN disclosed
EP-4137487-A1 PROCESS FOR THE PREPARATION OF A SULFONAMIDE STRUCTURED KINASE INHIBITOR Aurigene Discovery Technologies Limited (IN) 2023-02-22 EP disclosed
EP-3601262-B1 PROCESS FOR THE PREPARATION OF A SULFONAMIDE STRUCTURED KINASE INHIBITOR AURIGENE DISCOVERY TECH LTD (IN) 2022-11-09 EP disclosed
US-11332460-B2 Process for the preparation of a sulfonamide structured kinase inhibitor ORION CORPORATION (FI) 2022-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332460-B2 Process for the preparation of a sulfonamide structured kinase inhibitor FGFR1, FGFR2, FGFR4 ALDH1A1 1024/4885TTR 4052/4885KDM4E 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.